Holen Sie sich die Stockscreener-App
2.39
1.24%
-0.03
Schlusskurs vom Vortag:
$2.42
Offen:
$2.3578
24-Stunden-Volumen:
173.20K
Relative Volume:
1.44
Marktkapitalisierung:
$11.65M
Einnahmen:
$468.00K
Nettoeinkommen (Verlust:
$-10.34M
KGV:
-0.339
EPS:
-7.05
Netto-Cashflow:
$-8.94M
1W Leistung:
+12.74%
1M Leistung:
+6.22%
6M Leistung:
+12.40%
1J Leistung:
-23.52%
1-Tages-Spanne:
$2.3109
$2.405
1-Wochen-Bereich:
$2.07
$2.45
52-Wochen-Spanne:
$1.625
$4.66
Biocardia Inc Stock (BCDA) Company Profile
Firmenname
Biocardia Inc
Sektor
Branche
Telefon
650-226-0123
Adresse
320 SOQUEL WAY, SUNNYVALE, CA
Vergleichen Sie BCDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.5846 | 544.73M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.25 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.171 | 316.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
3.14 | 118.42M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.24 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-16 | Herabstufung | Dawson James | Buy → Neutral |
Biocardia Inc Aktie (BCDA) Neueste Nachrichten
BioCardia files prospectus for resale of 549K shares; stock down 8.6% - MSN
BioCardia Registers 549,392 Shares for Potential Resale by Investors - MarketScreener
BioCardia (BCDA) Proposes Offering of 549K Common Shares | BCDA Stock News - GuruFocus
BCDA boosts ATM capacity to $3.63M; float rules cap issuance | BCDAW SEC FilingForm 424B5 - Stock Titan
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial - Newsfile
Insider Buying: David Mcclung Acquires Shares of BioCardia Inc (BCDA) - GuruFocus
BioCardia Completes Private Placement Agreement - TipRanks
Biocardia CEO Peter Altman acquires $1,488 in common stock - MSN
BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System - Yahoo Finance
BCDABioCardia Reports First Quarter 2025 Business Highlights and Financial Results - Revista ADVFN
Biocardia CEO Peter Altman acquires $221 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $221 in company stock - Investing.com
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Heal - GuruFocus
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - The Manila Times
BioCardia Reveals Latest Progress on Revolutionary Cell Therapy for Heart Failure at Major Healthcare Conference - Stock Titan
BioCardia, Inc. (NASDAQ:BCDA) Q1 2025 Earnings Call Transcript - Insider Monkey
BioCardia’s Earnings Call: Progress Amid Financial Strain - TipRanks
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - Yahoo Finance
Biocardia 2024 Q2 Earnings Misses Targets as Revenue Declines 93% - AInvest
BioCardia Reports Positive Q1 2025 Progress - TipRanks
Earnings call transcript: BioCardia’s Q1 2025 results show clinical progress - Investing.com
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Reports Groundbreaking Heart Failure Trial Results: 82% Reduction in Angina Episodes - Stock Titan
BioCardia’s Hidden Catalysts: Why Cardiac Regenerative Medicine’s Next Breakthrough Is Undervalued - AInvest
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - The Manila Times
BioCardia to Host Q1 2025 Corporate Update and Financial Results - GuruFocus
Insider Buying Surges in May. Especially These 5 Stocks - 24/7 Wall St.
BioCardia (BCDA) Expands Enrollment for Phase 3 CardiAMP HF II T - GuruFocus
BioCardia Advances Phase 3 CardiAMP HF II Trial - TipRanks
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Trial | BCDA Stock News - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com Nigeria
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
Finanzdaten der Biocardia Inc-Aktie (BCDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocardia Inc-Aktie (BCDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Jun 30 '25 |
Buy |
2.08 |
24,096 |
49,999 |
165,862 |
| STERTZER SIMON H | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
192,654 |
| Blank Andrew Scott | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
346,023 |
| Altman Peter | President and CEO |
May 30 '25 |
Buy |
2.21 |
100 |
221 |
141,766 |
| Altman Peter | President and CEO |
May 20 '25 |
Buy |
2.08 |
1,600 |
3,328 |
140,966 |
| Altman Peter | President and CEO |
May 22 '25 |
Buy |
1.89 |
700 |
1,323 |
141,666 |
| Altman Peter | President and CEO |
May 16 '25 |
Buy |
2.43 |
300 |
730 |
139,366 |
| Altman Peter | President and CEO |
May 14 '25 |
Buy |
2.99 |
100 |
299 |
139,066 |
| KRASNO RICHARD M | Director |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
16,268 |
| McClung David | Chief Financial Officer |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
43,131 |
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):